Poster Presentation at the Asco Annual Meeting Titled, “AKY-2519, a Novel B7-H3-targeted Radioconjugate, Demonstrates a Differentiated Biodistribution profile with low normal tissue exposure and robust tumor doses in patients with MCRPC”